



# FOURTH-QUARTER AND FULL-YEAR 2024 RESULTS

## TOTAL COMPANY

### WORLDWIDE SALES

Q4 **\$11.0B** **10.1%**<sup>1</sup>


FULL YEAR **\$42.0B** **9.6%**<sup>2</sup>

### ORGANIC\* SALES GROWTH FOR UNDERLYING BASE BUSINESS\*\*

## MORE THAN 15 NEW GROWTH OPPORTUNITIES ANNOUNCED IN 2024, INCLUDING:

### FIRST-OF-ITS-KIND DEVICE TO REPAIR LEAKY TRICUSPID HEART VALVE

- ▶ FDA approval for TriClip™ transcatheter edge-to-edge repair (TEER) system.
- ▶ System is specifically designed for the treatment of tricuspid regurgitation (TR), or a leaky tricuspid valve.



**ACHIEVED UPPER END OF INITIAL GUIDANCE RANGES PROVIDED IN JANUARY 2024 FOR ORGANIC SALES GROWTH AND ADJUSTED EARNINGS PER SHARE**

### INNOVATION IN CONCUSSION ASSESSMENT

- ▶ FDA clearance for i-STAT® TBI cartridge, which helps assess a person with a suspected traumatic brain injury (TBI).
- ▶ Test can be performed outside of traditional hospital settings, making it more accessible and convenient for patients.



### EXPANDING IN BIOWEARABLES

- ▶ FDA clearance for Lingo™, our first continuous glucose monitoring system available without a prescription and designed for people interested in improving their overall health and wellness.
- ▶ System is based on Abbott's world leading FreeStyle Libre® continuous glucose monitoring technology.



## KEY BUSINESS UNITS<sup>3</sup>

### FOURTH-QUARTER ORGANIC\* SALES GROWTH FOR UNDERLYING BASE BUSINESS\*\*



**14.0%**  
MEDICAL DEVICES



**6.1%**  
DIAGNOSTICS  
Excludes the impact of COVID-19 testing sales



**7.1%**  
NUTRITION



**8.5%**  
ESTABLISHED PHARMACEUTICALS

## FULL-YEAR 2025 GUIDANCE<sup>4</sup>

**7.5% to 8.5%**  
ORGANIC SALES GROWTH

**\$5.05 to \$5.25**  
ADJUSTED DILUTED EPS

<sup>1</sup>Organic sales growth excludes impact of foreign exchange and the impact of discontinuing the ZonePerfect® product line in the Nutrition business. For full financial data and reconciliation of non-GAAP measures, please see our press release dated Jan. 22, 2025, available at [www.abbottinvestor.com](http://www.abbottinvestor.com).  
<sup>2</sup>Excludes the impact of COVID-19 testing sales.  
<sup>3</sup>The Lingo Glucose System is intended for users 18 years and older not on insulin. It is not intended for diagnosis of diseases, including diabetes. The Lingo program does not guarantee that everyone will achieve the same results as individual responses may vary. Consult your healthcare professional before making changes to your diet or exercise regimen or if you have an eating disorder or a history of eating disorders.  
<sup>4</sup>Find important safety information about the FreeStyle Libre portfolio: [www.freestylelibre.us/safety-information](http://www.freestylelibre.us/safety-information).

1. On a GAAP basis, fourth-quarter Abbott sales increased 7.2%. 2. On a GAAP basis, full-year Abbott sales increased 4.6%. 3. On a GAAP basis, fourth-quarter Medical Devices sales increased 13.7%, Diagnostics sales decreased 0.6%, Nutrition sales increased 4.5% and Established Pharmaceuticals sales increased 3.8%. 4. Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.

### FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.